TY - JOUR AU - Firriolo, F. J. AU - Hupp, W. S. PY - 2012 DA - 2012// TI - Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients JO - Oral Surg Oral Med Oral Pathol Oral Radiol VL - 113 UR - https://doi.org/10.1016/j.oooo.2011.10.005 DO - 10.1016/j.oooo.2011.10.005 ID - Firriolo2012 ER - TY - STD TI - European Medicines Agency/Committee for Medical Products for Human Use: Lixiana (edoxaban). http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002629/WC500186182.pdf. Accessed 11 May 2015. UR - http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002629/WC500186182.pdf ID - ref2 ER - TY - JOUR AU - Romond, K. K. AU - Miller, C. S. AU - Henry, R. G. PY - 2013 DA - 2013// TI - Dental management considerations for a patient taking dabigatran etexilate: a case report JO - Oral Surg Oral Med Oral Pathol Oral Radiol VL - 116 UR - https://doi.org/10.1016/j.oooo.2013.05.001 DO - 10.1016/j.oooo.2013.05.001 ID - Romond2013 ER - TY - JOUR AU - Mingarro-de-León, A. AU - Chaveli-López, B. PY - 2013 DA - 2013// TI - Alternative to oral dicoumarin anticoagulants: Considerations in dental care JO - J Clin Exp Dent VL - 5 UR - https://doi.org/10.4317/jced.51226 DO - 10.4317/jced.51226 ID - Mingarro-de-León2013 ER - TY - JOUR AU - Levy, J. H. AU - Key, N. S. AU - Azran, M. S. PY - 2010 DA - 2010// TI - Novel oral anticoagulants: implications in the perioperative setting JO - Anesthesiology VL - 113 ID - Levy2010 ER - TY - JOUR AU - O’Connell, J. E. AU - Stassen, L. F. PY - 2014 DA - 2014// TI - New oral anticoagulants and their implications for dental patients JO - J Ir Dent Assoc VL - 60 ID - O’Connell2014 ER - TY - STD TI - Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al.;RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. ID - ref7 ER - TY - JOUR AU - Sorensen, S. V. AU - Kansal, A. R. AU - Connolly, S. AU - Linnehan, J. AU - Bradley-Kennedy, C. PY - 2011 DA - 2011// TI - Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective JO - Thromb Haemost. VL - 105 UR - https://doi.org/10.1160/TH11-02-0089 DO - 10.1160/TH11-02-0089 ID - Sorensen2011 ER - TY - JOUR AU - Ryn, J. AU - Stangier, J. AU - Haertter, S. AU - Liesenfeld, K. H. AU - Wienen, W. AU - Feuring, M. PY - 2010 DA - 2010// TI - Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity JO - Thromb Haemost. VL - 103 UR - https://doi.org/10.1160/TH09-11-0758 DO - 10.1160/TH09-11-0758 ID - Ryn2010 ER - TY - JOUR AU - Castellone, D. D. AU - Cott, E. M. PY - 2010 DA - 2010// TI - Laboratory monitoring of new anticoagulants JO - Am J Hematol VL - 85 UR - https://doi.org/10.1002/ajh.21718 DO - 10.1002/ajh.21718 ID - Castellone2010 ER - TY - JOUR AU - Thompson, C. A. PY - 2010 DA - 2010// TI - First oral thrombin inhibitor enters market: drug does not require clinicians to monitor INR JO - Am J Health Syst Pharm VL - 67 UR - https://doi.org/10.2146/news100078 DO - 10.2146/news100078 ID - Thompson2010 ER - TY - JOUR AU - Davis, C. AU - Robertson, C. AU - Shivakumar, S. AU - Lee, M. PY - 2013 DA - 2013// TI - Implications of Dabigatran, a direct thrombin inhibitor, for oral surgery practice JO - J Can Dent Assoc VL - 79 ID - Davis2013 ER - TY - JOUR AU - Dubois, E. A. AU - Cohen, A. F. PY - 2010 DA - 2010// TI - Dabigatran etexilate JO - Br J Clin Pharmacol VL - 70 UR - https://doi.org/10.1111/j.1365-2125.2010.03644.x DO - 10.1111/j.1365-2125.2010.03644.x ID - Dubois2010 ER - TY - STD TI - U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed 9 November 2015. UR - https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails ID - ref14 ER - TY - JOUR AU - Pollack, C. V. AU - Reilly, P. A. AU - Eikelboom, J. PY - 2015 DA - 2015// TI - Idarucizumab for Dabigatran Reversal JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1502000 DO - 10.1056/NEJMoa1502000 ID - Pollack2015 ER - TY - JOUR AU - Eerenberg, E. S. AU - Kamphuisen, P. W. AU - Sijpkens, M. K. AU - Meijers, J. C. AU - Buller, H. R. AU - Levi, M. PY - 2011 DA - 2011// TI - Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects JO - Circulation. VL - 124 UR - https://doi.org/10.1161/CIRCULATIONAHA.111.029017 DO - 10.1161/CIRCULATIONAHA.111.029017 ID - Eerenberg2011 ER - TY - JOUR AU - Wynn, R. L. PY - 2012 DA - 2012// TI - New antiplatelet and anticoagulant drugs JO - Gen Dent VL - 60 ID - Wynn2012 ER - TY - JOUR AU - Healey, J. S. AU - Eikelboom, J. AU - Douketis, J. PY - 2012 DA - 2012// TI - Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial JO - Circulation VL - 126 UR - https://doi.org/10.1161/CIRCULATIONAHA.111.090464 DO - 10.1161/CIRCULATIONAHA.111.090464 ID - Healey2012 ER - TY - JOUR AU - Douketis, J. D. AU - Healey, J. S. AU - Brueckmann, M. AU - Wallentin, L. AU - Oldgren, J. AU - Yang, S. PY - 2015 DA - 2015// TI - Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial JO - Thromb Haemost VL - 113 UR - https://doi.org/10.1160/TH14-04-0305 DO - 10.1160/TH14-04-0305 ID - Douketis2015 ER - TY - JOUR AU - Eikelboom, J. W. AU - Wallentin, L. AU - Connolly, S. J. AU - Ezekowitz, M. AU - Healey, J. S. AU - Oldgren, J. PY - 2011 DA - 2011// TI - Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial JO - Circulation. VL - 123 UR - https://doi.org/10.1161/CIRCULATIONAHA.110.004747 DO - 10.1161/CIRCULATIONAHA.110.004747 ID - Eikelboom2011 ER - TY - JOUR AU - Borea, G. AU - Montebugnoli, L. AU - Capuzzi, P. AU - Magelli, C. PY - 1993 DA - 1993// TI - Tranexamic acid as a mouthwash in anticoagulant-treated patients undergoing oral surgery. An alternative method to discontinuing anticoagulant therapy JO - Oral Surg Oral Med Oral Pathol VL - 75 UR - https://doi.org/10.1016/0030-4220(93)90401-O DO - 10.1016/0030-4220(93)90401-O ID - Borea1993 ER - TY - JOUR AU - Bacci, C. AU - Maglione, M. AU - Favero, L. AU - Perini, A. AU - Lenarda, R. AU - Berengo, M. PY - 2010 DA - 2010// TI - Management of dental extraction in patients undergoing anticoagulant treatment. Results from a large, multicentre, prospective, case–control study JO - Thromb Haemost VL - 104 UR - https://doi.org/10.1160/TH10-02-0139 DO - 10.1160/TH10-02-0139 ID - Bacci2010 ER - TY - JOUR AU - Legrand, M. AU - Mateo, J. AU - Aribaud, A. AU - Ginisty, S. AU - Eftekhari, P. AU - Huy, P. T. PY - 2011 DA - 2011// TI - The use of dabigatran in elderly patients JO - Arch Intern Med. VL - 171 UR - https://doi.org/10.1001/archinternmed.2011.314 DO - 10.1001/archinternmed.2011.314 ID - Legrand2011 ER - TY - JOUR PY - 2010 DA - 2010// TI - Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study JO - Am Heart J VL - 159 UR - https://doi.org/10.1016/j.ahj.2009.11.025 DO - 10.1016/j.ahj.2009.11.025 ID - ref24 ER - TY - JOUR AU - Bruins Slot, K. M. AU - Berge, E. PY - 2013 DA - 2013// TI - Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation JO - Cochrane Database Syst Rev VL - 8 ID - Bruins Slot2013 ER - TY - JOUR AU - Nunes, J. P. AU - Rodrigues, R. P. AU - Gonçalves, F. R. PY - 2014 DA - 2014// TI - Comparative analysis and meta-analysis of major clinical trials with oral factor Xa inhibitors versus warfarin in atrial fibrillation JO - Open Heart VL - 1 UR - https://doi.org/10.1136/openhrt-2014-000080 DO - 10.1136/openhrt-2014-000080 ID - Nunes2014 ER - TY - JOUR AU - Tsiara, S. AU - Pappas, K. AU - Boutsis, D. AU - Laffan, M. PY - 2011 DA - 2011// TI - New oral anticoagulants: should they replace heparins and warfarin? JO - Hellenic J Cardiol. VL - 52 ID - Tsiara2011 ER - TY - JOUR AU - Das, A. AU - Liu, D. PY - 2015 DA - 2015// TI - Novel antidotes for target specific oral anticoagulants JO - Exp Hematol Oncol VL - 4 UR - https://doi.org/10.1186/s40164-015-0020-3 DO - 10.1186/s40164-015-0020-3 ID - Das2015 ER - TY - JOUR AU - Mehta, R. S. PY - 2010 DA - 2010// TI - Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: part I (Factor Xa inhibitors) JO - Expert Rev Hematol VL - 3 UR - https://doi.org/10.1586/ehm.10.5 DO - 10.1586/ehm.10.5 ID - Mehta2010 ER - TY - STD TI - Sherwood MW, Douketis JD, Patel MR, Piccini JP, Hellkamp AS, Lokhnygina Y, et al.; ROCKET AF Investigators. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014;129:1850–9. ID - ref30 ER - TY - JOUR AU - Turpie, A. G. AU - Kreutz, R. AU - Llau, J. AU - Norrving, B. AU - Haas, S. PY - 2012 DA - 2012// TI - Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor JO - Thromb Haemost. VL - 108 UR - https://doi.org/10.1160/TH12-03-0209 DO - 10.1160/TH12-03-0209 ID - Turpie2012 ER - TY - JOUR AU - Kubitza, D. AU - Becka, M. AU - Mueck, W. AU - Zuehlsdorf, M. PY - 2007 DA - 2007// TI - Rivaroxaban (BAY 59–7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen JO - Br J Clin Pharmacol. VL - 63 UR - https://doi.org/10.1111/j.1365-2125.2006.02776.x DO - 10.1111/j.1365-2125.2006.02776.x ID - Kubitza2007 ER - TY - JOUR AU - Garcia, D. AU - Alexander, J. H. AU - Wallentin, L. AU - Wojdyla, D. M. AU - Thomas, L. AU - Hanna, M. PY - 2014 DA - 2014// TI - Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures JO - Blood. VL - 124 UR - https://doi.org/10.1182/blood-2014-08-595496 DO - 10.1182/blood-2014-08-595496 ID - Garcia2014 ER - TY - JOUR AU - Blinder, D. AU - Manor, Y. AU - Martinowitz, U. PY - 2001 DA - 2001// TI - Dental extractions in patients maintained on oral anticoagulant therapy: comparison of INR value with occurrence of postoperative bleeding JO - Int J Oral Maxillofac Surg VL - 30 UR - https://doi.org/10.1054/ijom.2001.0172 DO - 10.1054/ijom.2001.0172 ID - Blinder2001 ER - TY - JOUR AU - Malden, N. PY - 2005 DA - 2005// TI - Dental procedures can be undertaken without alteration of oral anticoagulant regimen JO - Evid Based Dent VL - 6 UR - https://doi.org/10.1038/sj.ebd.6400309 DO - 10.1038/sj.ebd.6400309 ID - Malden2005 ER - TY - JOUR AU - Hong, C. H. AU - Islam, I. PY - 2013 DA - 2013// TI - Anti-Thrombotic Therapy: Implications for Invasive Outpatient Procedures in Dentistry JO - J Blood Disorders Transf VL - 4 ID - Hong2013 ER - TY - JOUR AU - Breik, O. AU - Tadros, R. AU - Devitt, P. PY - 2013 DA - 2013// TI - Thrombin inhibitors: surgical considerations and pharmacology JO - ANZ J Surg VL - 83 UR - https://doi.org/10.1111/ans.12078 DO - 10.1111/ans.12078 ID - Breik2013 ER -